米国および欧州の軟骨再生市場、タイプ別（硝子軟骨、線維軟骨、弾性軟骨）、治療法（細胞ベースおよび非細胞ベース）、治療タイプ（内因性修復刺激および緩和療法）、適用部位（膝、股関節、足首、脊椎、その他）、外科的処置（骨軟骨移植、自家軟骨細胞移植、マトリックス自家軟骨移植（MACI）、軟骨形成術およびマイクロフラクチャー、骨切り術、関節鏡検査、擦過関節形成術、若年性同種移植片断片、その他）、エンドユーザー（病院および診療所、学術研究機関、外来手術センター、矯正センター、その他） - 2031年までの業界動向および予測。
米国とヨーロッパの軟骨再生市場の分析と規模
市場の成長を牽引する主な要因の 1 つは、変形性関節症の罹患率の上昇です。さらに、研究開発活動への投資の増加も、市場の成長の重要な推進力となっています。高度な医療インフラを推進する政府の取り組みも市場に影響を与えています。しかし、熟練した専門家の不足と、整形外科用インプラントや手術に関連する高コストが、市場の成長を抑制しています。
データブリッジマーケットリサーチは、米国とヨーロッパの軟骨再生市場は、2024年から2031年の予測期間中に12.8％のCAGRで成長し、2023年の590,964.54米ドルから2031年には1,474,396.99米ドルに達すると予測しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2024年から2031年 |
|
基準年 |
2023 |
|
歴史的な年 |
2022 (2016～2021年にカスタマイズ可能) |
|
定量単位 |
収益（千米ドル） |
|
対象セグメント |
タイプ（硝子軟骨、線維軟骨、弾性軟骨）、治療法（細胞ベースおよび非細胞ベース）、治療タイプ（内因性修復刺激および緩和療法）、適用部位（膝、股関節、足首、脊椎、その他）、手術手順（骨軟骨移植、自家軟骨細胞移植、マトリックス自家軟骨移植（MACI）、軟骨形成術およびマイクロフラクチャー、骨切り術、関節鏡検査、擦過関節形成術、若年性同種移植片、その他）、エンドユーザー（病院および診療所、学術研究機関、外来手術センター、矯正センター、その他） |
|
対象国 |
米国、ドイツ、英国、フランス、イタリア、スペイン、ロシア、ポーランド、スイス、オランダ、トルコ、スウェーデン、ベルギー、デンマーク、フィンランド、ノルウェー、その他のヨーロッパ諸国 |
|
対象となる市場プレーヤー |
Zimmer Biomet、Vericel Corporation、Arthrex、Inc.、CONMED Corporation、RTI Surgical、Smith+Nephew、Anika Therapeutics、Inc.、Geistlich Pharma AG、AlloSource、TETEC AG（B. Braun SEの子会社）、meidrix biomedicals GmbH、Bioinova、as、Lamina Therapeutics、CO.DON、Novartis AG、Cartilage Inc.、Histogen Inc.など |
市場の定義
軟骨再生とは、人体の損傷または変性した軟骨組織を修復するための医療技術および治療法の開発と応用を指します。軟骨は関節を支え、クッションとして機能する重要な役割を果たす結合組織であり、外傷、関節炎、またはその他の変性疾患によって損傷を受けることがあります。
米国と欧州の軟骨再生市場の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 変形性関節症の罹患率の上昇
変形性関節症は高齢者に多く見られ、高齢化人口の増加に伴い、この疾患の発症率も高くなっています。加齢により、関節は変形性関節症にかかりやすくなります。そのため、高齢者層は軟骨再生療法の大きな市場となっています。肥満は、特に膝や股関節などの体重を支える関節において、変形性関節症の確立された危険因子です。世界的な肥満率の上昇は、特に若年層における変形性関節症の発症率の上昇につながっています。肥満の人は、関節にかかるストレスが大きくなり、軟骨の変性が加速するため、再生ソリューションの需要が生まれます。
変形性関節症の罹患率の上昇は、軟骨再生市場の成長を牽引する強力な要因です。軟骨損傷に対処するための高度な再生ソリューションの需要は、地域の人口が高齢化し、変形性関節症のリスク要因が続くにつれて、引き続き増加すると予想されます。変形性関節症に関連する医療ニーズの高まりに対応するために、市場ではさらなる進歩、研究、革新が見られる可能性があります。
- 研究開発活動への投資の増加
研究開発投資の増加により、再生医療における先進技術の探究と開発が促進されます。幹細胞療法、組織工学、3Dバイオプリンティングなどの技術は継続的に進化しており、軟骨再生のためのより効果的で正確なソリューションを提供しています。研究開発活動により、軟骨再生用に特別に設計された新しい製品が生まれます。製薬会社とバイオテクノロジー企業は、軟骨修復の複雑さに対処し、患者の転帰を改善できる新しい医薬品、生物製剤、医療機器の開発に投資しています。
多額の研究開発投資により、臨床試験の開始と進行が可能になります。これらの試験は、新しい軟骨再生療法の安全性と有効性を評価するために不可欠です。試験結果が良好であれば、これらの治療法の規制当局による承認と最終的な商品化につながります。研究開発の取り組みは、軟骨の変性と再生のメカニズムをより深く理解することにつながります。この知識は、さまざまな程度の軟骨損傷を持つ患者の特定のニーズに対応できる、ターゲットを絞った個別化された治療法を開発するために不可欠です。
研究開発活動への投資の増加は、イノベーションの促進、治療法の改善、科学的理解の促進、そして最終的には軟骨関連疾患の患者に新しい効果的なソリューションをもたらすことで、市場の成長を促進します。これらの投資は市場の進化に貢献し、市場の成長を牽引する再生医療の幅広い分野の中で、ダイナミックで反応の速いセクターとして位置づけています。
機会
- 低侵襲手術の需要増加
低侵襲処置（または低侵襲手術）には、必要な切開の大きさを制限する外科技術が含まれます。これにより、創傷治癒時間、関連する痛み、および感染リスクが軽減されます。手術は定義上、侵襲的であり、ある程度の大きさの切開を必要とする多くの手術は開腹手術と呼ばれます。低侵襲手術には、関節置換術、スポーツ傷害の関節鏡修復、および複雑な筋骨格疾患の顕微鏡治療が含まれます。低侵襲手術には、回復時間が短く、感染リスクが低く、出血が少なく、傷跡が小さく、入院期間が短いという特徴があります。
MIS で使用されるナビゲーション支援手術装置などの技術と器具により、開腹手術の場合よりも身体へのダメージが少なくなります。さまざまな障害を持つ患者を手術するための低侵襲技術の継続的な進歩により、軟骨再生市場の成長が促進されると予想されます。
高度な技術によって行われる低侵襲手術の利点は莫大です。低侵襲手術の需要が高まることで、市場の成長機会が生まれることが期待されます。
抑制/挑戦
- 軟骨再生に対する不十分な償還シナリオ
軟骨再生療法には、高度で革新的な技術が用いられることが多く、高額になることがあります。償還が不十分な場合、患者の自己負担額が高額になり、これらの治療費を負担する余裕が制限される可能性があります。この金銭的障壁により、患者は軟骨再生処置を選択することを思いとどまり、市場の需要が減少する可能性があります。償還ポリシーで費用が十分にカバーされている場合、医師や医療提供者は軟骨再生療法を採用し、推奨する可能性が高くなります。償還が不十分な場合、医療従事者は患者や診療への経済的影響を懸念し、これらの治療の提供をためらう可能性があります。
競争の激しい医療分野では、償還ポリシーが市場の動向に大きな影響を与える可能性があります。軟骨再生療法の償還が制限されていたり、一貫性がなかったりすると、従来の治療法や代替治療法と比較してこれらの治療法の競争力が損なわれる可能性があります。その結果、市場の成長の可能性が制限されます。
軟骨再生技術の導入は遅く、強力な償還サポートがなければ主流の医療行為への統合が制限される可能性があります。その結果、市場の拡大と、整形外科的疾患や怪我に対処する潜在能力の完全な実現が制限されます。
最近の動向
- 2023年5月、カリフォルニア大学アーバイン校のバイオメディカルスタートアップであるCartilage Inc.は、失われた組織を再生し、顎関節の欠陥を修復することでTMJ機能を回復する製品を開発しています。これにより、同社は製品ポートフォリオを強化することができました。
- ノバルティスAGは2021年9月、米国食品医薬品局（FDA）が膝関節炎の治療薬LNA043にファストトラック指定を与えたと発表した。これにより同社は変形性関節症製品分野での存在感を確立することができた。
- 2020年9月、ラミナ・セラピューティクスは、INSERM UMR 1260 / RNM（再生ナノ医療）ユニットのディレクターであり、ラミナ・セラピューティクスの創設メンバーであるナディア・ジェッセル教授がコーディネートするストラスブールの科学チームの研究作業に依存していることを発表しました。この革新的な技術は、特に骨、軟骨、骨軟骨ユニットの再建のための再生医療用の新世代の複合先進治療医薬品（cATMP）の開発を目指しています。
- 2021年1月、スポーツ医学および重度熱傷治療市場における先進的治療法のリーダーであるVericel Corporationは、United HealthcareがMACI（豚コラーゲン膜上の自己培養軟骨細胞）の医療ポリシーを拡大し、膝蓋骨の症状のある全層軟骨欠損および膝の複数の軟骨欠損の患者もカバーすると発表した。
- 2020年10月、Cartilage Inc.は国立衛生研究所（NIH）からフェーズIの25万2000米ドルの中小企業イノベーション研究（SBIR）助成金を受け取った。このスタートアップは、この助成金を使用して、治癒能力のあるスキャフォールドフリーの組織工学軟骨インプラントである自社製品Hyaleonの実現可能性を調査した。
米国と欧州の軟骨再生市場の範囲
米国とヨーロッパの軟骨再生市場は、タイプ、治療様式、治療の種類、適用部位、外科的処置、エンドユーザーなど、6 つの主要なセグメントに分かれています。これらのセグメントの成長は、業界のわずかな成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供して、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。
タイプ
- 硝子軟骨
- 線維軟骨
- 弾性軟骨
タイプに基づいて、米国とヨーロッパの軟骨再生市場は、硝子軟骨、線維軟骨、弾性軟骨に分類されます。
治療法
- 細胞ベース
- 非細胞ベース
治療法に基づいて、米国とヨーロッパの軟骨再生市場は細胞ベースと非細胞ベースに分類されます。
治療の種類
- 内因性修復刺激
- 緩和的
治療の種類に基づいて、米国とヨーロッパの軟骨再生市場は、内因性修復刺激と緩和に分類されます。
応募サイト
- 膝
- ヒップ
- 足首
- 脊椎
- その他
適用部位に基づいて、米国とヨーロッパの軟骨再生市場は、膝、股関節、足首、脊椎、その他に分類されます。
手術手順
- 骨軟骨移植
- 自家軟骨細胞移植
- マトリックス自己軟骨移植（MACI）
- 軟骨形成術とマイクロフラクチャー
- 骨切り術
- 関節鏡検査
- 摩耗関節形成術
- 若年性同種移植片断片
- その他
外科手術に基づいて、米国とヨーロッパの軟骨再生市場は、骨軟骨移植、自家軟骨細胞移植、マトリックス自家軟骨移植（MACI）、軟骨形成術および微小骨折、骨切り術、関節鏡検査、擦過関節形成術、若年性同種移植片断片、その他に分類されます。
エンドユーザー
- 病院と診療所
- 学術研究機関
- 外来手術センター
- オルソセンター
- その他
エンドユーザーに基づいて、米国とヨーロッパの軟骨再生市場は、病院と診療所、学術研究機関、外来手術センター、オルソセンター、その他に分類されます。
米国と欧州の軟骨再生市場の地域分析/洞察
米国とヨーロッパの軟骨再生市場が分析され、市場規模の洞察と傾向が国、タイプ、治療法、治療の種類、適用部位、外科手術、およびエンドユーザー別に提供されます。
この市場レポートで取り上げられている国は、米国、ドイツ、英国、フランス、イタリア、スペイン、ロシア、ポーランド、スイス、オランダ、トルコ、スウェーデン、ベルギー、デンマーク、フィンランド、ノルウェー、およびその他のヨーロッパ諸国です。
米国は、さまざまなメーカーによる投資レベルの高さと医薬品製造の需要増加により、米国と欧州の軟骨再生市場を支配すると予想されています。ドイツは、研究開発活動への投資の増加により、欧州の軟骨再生市場を支配すると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、地域ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、国内関税の影響、貿易ルートも考慮されます。
米国と欧州の軟骨再生市場：競争環境とシェア分析
米国およびヨーロッパの軟骨再生市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、生み出される収益、市場の可能性、新しい市場への取り組み、地域的プレゼンス、生産拠点と施設、生産能力、会社の長所と短所、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、市場に関連する会社の焦点にのみ関連しています。
米国およびヨーロッパの軟骨再生市場で活動している主要な市場プレーヤーとしては、Zimmer Biomet、Vericel Corporation、Arthrex、Inc.、CONMED Corporation、RTI Surgical、Smith+Nephew、Anika Therapeutics、Inc.、Geistlich Pharma AG などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE U.S. & EU CARTILAGE REGENERATION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PSETEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 NUMBER OF PROCEDURES PERFORMED PER YEAR: BY COUNTRY
6 REGULATIONS
6.1 EUROPE CARTILAGE REGENERATION MARKET: REGULATIONS
6.1.1 CONFORMITY
6.1.2 CLINICAL INVESTIGATION
6.2 U.S. CARTLAGE REPAIRING MARKET: REGULATIONS
6.2.1 FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH (CDRH)
6.2.2 FDA CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER)
6.2.3 CLINICAL TRIALS OVERSIGHT
6.2.4 POST-MARKET SURVEILLANCE
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF OSTEOARTHRITIS
7.1.2 RISING INVESTMENTS IN RESEARCH AND DEVELOPMENT ACTIVITIES
7.1.3 RISING HEALTHCARE EXPENDITURE TO PROMOTE CARTILAGE REGENERATION TREATMENT
7.1.4 INCREASING NUMBER OF JOINT INJURIES
7.2 RESTRAINTS
7.2.1 POOR REIMBURSEMENT SCENARIO FOR CARTILAGE REGENERATION
7.2.2 STRINGENT REGULATIONS FOR THE APPROVAL OF CARTILAGE REGENERATION PRODUCTS
7.3 OPPORTUNITIES
7.3.1 INCREASE DEMAND FOR MINIMALLY INVASIVE PROCEDURES
7.3.2 RISING TECHNOLOGICAL ADVANCEMENTS IN THE CARTILAGE REGENERATION PROCESS.
7.3.3 RISING AWARENESS OF MEDICAL TREATMENT IN EUROPE
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS IN HEALTHCARE MARKET
7.4.2 HIGH COST OF ORTHOPEDIC IMPLANTS AND SURGERIES
8 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TYPE
8.1 OVERVIEW
8.2 HYALINE CARTILAGE
8.3 FIBRO CARTILAGE
8.3.1 INTRA-ARTICULAR FIBROCARTILAGE
8.3.2 STRATIFORM FIBROCARTILAGE
8.3.3 CIRCUMFERENTIAL FIBROCARTILAGE
8.3.4 CONNECTING FIBROCARTILAGE
8.4 ELASTIC CARTILAGE
9 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY
9.1 OVERVIEW
9.2 CELL-BASED
9.2.1 CHONDROCYTE TRANSPLANTATION
9.2.1.1 AUTOLOGOUS CHONDROCYTE IMPLANTATION (ACI)
9.2.1.2 MATRIX-INDUCED AUTOLOGOUS CHONDROCYTE IMPLANTATION (MACI)
9.2.2 STEM CELLS
9.2.2.1 MESENCHYMAL STEM CELLS (MSC'S)
9.2.2.2 UMBILICAL CORD-DERIVED STEM CELL THERAPY
9.2.2.3 EMBRYONIC STEM CELL THERAPY
9.2.2.4 OTHERS
9.2.3 GROWTH FACTOR
9.2.3.1 PLATELET-RICH PLASMA (PRP)
9.2.3.2 AUTOLOGOUS CONDITIONED SERUM (ACS)
9.2.3.3 BONE MORPHOGENETIC PROTEIN (BMP) PRODUCTS
9.2.3.4 FIBROBLAST GROWTH FACTOR (FGF) PRODUCTS
9.2.3.5 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) PRODUCTS
9.2.3.6 OTHERS
9.2.4 OTHERS
9.3 NON - CELL BASED
9.3.1 SCAFFOLDS
9.3.1.1 NATURAL
9.3.1.1.1 HYALURONIC ACID (HA) PRODUCTS
9.3.1.1.2 COLLAGEN-BASED SCAFFOLDS
9.3.1.1.3 CHITOSAN SCAFFOLDS
9.3.1.1.4 DECELLULARIZED EXTRACELLULAR MATRIX
9.3.1.1.5 OTHERS
9.3.1.2 SYNTHETIC
9.3.1.2.1 POLY (LACTIC-CO-GLYCOLIC ACID) (PLGA) SCAFFOLDS
9.3.1.2.2 POLYETHYLENE GLYCOL (PEG) HYDROGELS:
9.3.1.2.3 OTHERS
9.3.2 CELL-FREE COMPOSITES
9.3.2.1 ARTIFICIAL CARTILAGE IMPLANT
9.3.2.2 OTHERS
10 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE
10.1 OVERVIEW
10.2 INTRINSIC REPAIR STIMULUS
10.3 PALLIATIVE
10.3.1 DEBRIDEMENT & LAVAGE
10.3.2 VISCOSUPPLEMENTATION
11 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE
11.1 OVERVIEW
11.2 KNEE
11.2.1 OSTEOCHONDRIAL GRAFTS TRANSPLANTATION
11.2.2 AUTOLOGOUS CHONDROCYTE
11.2.3 ARTHROSCOPIC CHONDROPLASTY
11.2.4 MICROFRACTURE
11.2.5 CELL-BASED CARTILAGE RESURFACING
11.2.6 OTHERS
11.3 HIP
11.4 ANKLE
11.5 SPINE
11.6 OTHERS
12 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURES
12.1 OVERVIEW
12.2 OSTEOCHONDRIAL TRANSPLANTATION
12.2.1 OSTEOCHONDRIAL AUTOGRAFT TRANSPLANTATION
12.2.2 OSTEOCHONDRIAL ALLOGRAFT TRANSPLANTATION
12.3 AUTOLOGOUS CHONDROCYTE IMPLANTATION
12.4 MATRIX AUTOLOGOUS CARTILAGE IMPLANTATION (MACI)
12.5 CHONDROPLASTY AND MICROFRACTURE
12.6 OSTEOTOMY
12.7 ARTHROSCOPY
12.8 ABRASION ARTHROPLASTY
12.9 JUVENILE ALLOGRAFT FRAGMENTS
12.1 OTHERS
13 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS AND CLINICS
13.2.1 PRIVATE
13.2.2 PUBLIC
13.3 ACADEMIC AND RESEARCH INSTITUTES
13.4 AMBULATORY SURGICAL CENTERS
13.5 ORTHOCENTERS
13.6 OTHERS
14 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY REGION
14.1 U.S.
14.2 EUROPE
14.2.1 GERMANY
14.2.2 U.K.
14.2.3 FRANCE
14.2.4 ITALY
14.2.5 SPAIN
14.2.6 RUSSIA
14.2.7 POLAND
14.2.8 SWITZERLAND
14.2.9 NETHERLANDS
14.2.10 TURKEY
14.2.11 SWEDEN
14.2.12 BELGIUM
14.2.13 DENMARK
14.2.14 FINLAND
14.2.15 NORWAY
14.2.16 REST OF EUROPE
15 U.S. CARTILAGE REGENERATION MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: U.S.
15.2 COMPANY SHARE ANALYSIS: EUROPE
16 COMPANY PROFILE
16.1 ZIMMER BIOMET
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 VERICEL CORPORATION.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENT
16.3 ARTHREX, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 PRODUCT PORTFOLIO
16.3.3 RECENT DEVELOPMENT
16.4 CONMED
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 RTI SURGICAL
16.5.1 COMPANY SNAPSHOT
16.5.2 PRODUCT PORTFOLIO
16.5.3 RECENT DEVELOPMENT
16.6 ALLOSOURCE
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 ANIKA THERAPEUTICS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 1.4.4 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 BIOINOVA, A.S.
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 CARTILAGE INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 CO.DON
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 GEISTLICH PHARMA AG
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 HISTOGEN INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 LAMINA THERAPEUTICS
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 MEIDRIX BIOMEDICALS GMBH
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 NOVARTIS AG
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 SMITH & NEPHEW
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 TETEC AG
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表のリスト
TABLE 1 U.S. NUMBER OF PROCEDURES PER YEAR
TABLE 2 GERMANY NUMBER OF PROCEDURES PER YEAR
TABLE 3 U.K. NUMBER OF PROCEDURES PER YEAR
TABLE 4 FRANCE NUMBER OF PROCEDURES PER YEAR
TABLE 5 ITALY NUMBER OF PROCEDURES PER YEAR
TABLE 6 SPAIN NUMBER OF PROCEDURES PER YEAR
TABLE 7 RUSSIA NUMBER OF PROCEDURES PER YEAR
TABLE 8 POLAND NUMBER OF PROCEDURES PER YEAR
TABLE 9 SWITZERLAND NUMBER OF PROCEDURES PER YEAR
TABLE 10 NETHERLANDS NUMBER OF PROCEDURES PER YEAR
TABLE 11 TURKEY NUMBER OF PROCEDURES PER YEAR
TABLE 12 SWEDEN NUMBER OF PROCEDURES PER YEAR
TABLE 13 BELGIUM NUMBER OF PROCEDURES PER YEAR
TABLE 14 DENMARK NUMBER OF PROCEDURES PER YEAR
TABLE 15 FINLAND NUMBER OF PROCEDURES PER YEAR
TABLE 16 NORWAY NUMBER OF PROCEDURES PER YEAR
TABLE 17 COST OF PROCEDURES
TABLE 18 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 19 U.S. & EUROPE FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 20 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 21 U.S. & EUROPE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 22 U.S. & EUROPE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 23 U.S. & EUROPE STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 24 U.S. & EUROPE GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 25 U.S. & EUROPE NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 26 U.S. & EUROPE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 27 U.S. & EUROPE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 28 U.S. & EUROPE SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 U.S. & EUROPE CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 30 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 U.S. & EUROPE PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 32 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 33 U.S. & EUROPE KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 34 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 35 U.S. & EUROPE OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 36 U.S. & EUROPE CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 37 U.S. & EUROPE HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 38 U.S. CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 39 U.S. FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 40 U.S. CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 41 U.S. CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 42 U.S. CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 43 U.S. STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 44 U.S. GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 45 U.S. NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 46 U.S. SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 47 U.S. NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 U.S. SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 49 U.S. CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 50 U.S. CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 U.S. PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 U.S. CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 53 U.S. KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 U.S. CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 55 U.S. OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 56 U.S. CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 57 U.S. HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 EUROPE CARTILAGE REGENERATION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 59 EUROPE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 60 EUROPE FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 61 EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 62 EUROPE CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 63 EUROPE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 64 EUROPE STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 65 EUROPE GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 66 EUROPE NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 67 EUROPE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 68 EUROPE NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 69 EUROPE SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 70 EUROPE CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 71 EUROPE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 EUROPE PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 73 EUROPE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 74 EUROPE KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 EUROPE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 76 EUROPE OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 EUROPE CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 78 EUROPE HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 GERMANY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 80 GERMANY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 81 GERMANY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 82 GERMANY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 83 GERMANY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 84 GERMANY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 85 GERMANY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 86 GERMANY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 87 GERMANY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 88 GERMANY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 GERMANY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 GERMANY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 91 GERMANY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 GERMANY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 GERMANY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 94 GERMANY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 95 GERMANY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 96 GERMANY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 GERMANY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 98 GERMANY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 99 U.K. CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 U.K. FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 101 U.K. CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 102 U.K. CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 103 U.K. CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 104 U.K. STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 105 U.K. GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 106 U.K. NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 107 U.K. SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 108 U.K. NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 109 U.K. SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 U.K. CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 111 U.K. CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 U.K. PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 113 U.K. CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 114 U.K. KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 115 U.K. CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 116 U.K. OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 U.K. CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 118 U.K. HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 119 FRANCE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 120 FRANCE FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 121 FRANCE CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 122 FRANCE CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 123 FRANCE CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 124 FRANCE STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 125 FRANCE GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 126 FRANCE NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 127 FRANCE SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 128 FRANCE NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 129 FRANCE SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 FRANCE CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 131 FRANCE CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 132 FRANCE PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 FRANCE CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 134 FRANCE KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 FRANCE CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 136 FRANCE OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 137 FRANCE CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 138 FRANCE HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 139 ITALY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 140 ITALY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 ITALY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 142 ITALY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 143 ITALY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 144 ITALY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 145 ITALY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 146 ITALY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 147 ITALY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 148 ITALY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 ITALY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 150 ITALY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 151 ITALY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 152 ITALY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 ITALY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 154 ITALY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 155 ITALY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 156 ITALY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 ITALY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 158 ITALY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 159 SPAIN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 160 SPAIN FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 161 SPAIN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 162 SPAIN CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 163 SPAIN CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 164 SPAIN STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 165 SPAIN GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 166 SPAIN NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 167 SPAIN SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 168 SPAIN NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 169 SPAIN SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 170 SPAIN CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 171 SPAIN CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 SPAIN PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 173 SPAIN CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 174 SPAIN KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 175 SPAIN CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 176 SPAIN OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 177 SPAIN CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 178 SPAIN HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 179 RUSSIA CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 180 RUSSIA FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 181 RUSSIA CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 182 RUSSIA CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 183 RUSSIA CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 184 RUSSIA STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 185 RUSSIA GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 186 RUSSIA NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 187 RUSSIA SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 188 RUSSIA NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 189 RUSSIA SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 190 RUSSIA CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 191 RUSSIA CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 192 RUSSIA PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 193 RUSSIA CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 194 RUSSIA KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 195 RUSSIA CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 196 RUSSIA OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 197 RUSSIA CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 198 RUSSIA HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 199 POLAND CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 200 POLAND FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 201 POLAND CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 202 POLAND CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 203 POLAND CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 204 POLAND STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 205 POLAND GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 206 POLAND NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 207 POLAND SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 208 POLAND NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 209 POLAND SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 210 POLAND CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 211 POLAND CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 212 POLAND PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 213 POLAND CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 214 POLAND KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 215 POLAND CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 216 POLAND OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 217 POLAND CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 218 POLAND HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 SWITZERLAND CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 220 SWITZERLAND FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 221 SWITZERLAND CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 222 SWITZERLAND CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 223 SWITZERLAND CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 224 SWITZERLAND STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 225 SWITZERLAND GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 226 SWITZERLAND NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 227 SWITZERLAND SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 228 SWITZERLAND NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 SWITZERLAND SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 230 SWITZERLAND CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 231 SWITZERLAND CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 232 SWITZERLAND PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 SWITZERLAND CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 234 SWITZERLAND KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 235 SWITZERLAND CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 236 SWITZERLAND OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 237 SWITZERLAND CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 238 SWITZERLAND HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 239 NETHERLANDS CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 240 NETHERLANDS FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 241 NETHERLANDS CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 242 NETHERLANDS CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 243 NETHERLANDS CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 244 NETHERLANDS STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 245 NETHERLANDS GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 246 NETHERLANDS NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 247 NETHERLANDS SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 248 NETHERLANDS NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 249 NETHERLANDS SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 250 NETHERLANDS CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 251 NETHERLANDS CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 252 NETHERLANDS PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 253 NETHERLANDS CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 254 NETHERLANDS KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 255 NETHERLANDS CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 256 NETHERLANDS OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 257 NETHERLANDS CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 258 NETHERLANDS HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 259 TURKEY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 260 TURKEY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 261 TURKEY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 262 TURKEY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 263 TURKEY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 264 TURKEY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 265 TURKEY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 266 TURKEY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 267 TURKEY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 268 TURKEY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 269 TURKEY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 270 TURKEY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 271 TURKEY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 272 TURKEY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 273 TURKEY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 274 TURKEY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 275 TURKEY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 276 TURKEY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 TURKEY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 278 TURKEY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 SWEDEN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 280 SWEDEN FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 281 SWEDEN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 282 SWEDEN CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 283 SWEDEN CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 284 SWEDEN STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 285 SWEDEN GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 286 SWEDEN NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 287 SWEDEN SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 288 SWEDEN NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 289 SWEDEN SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 290 SWEDEN CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 291 SWEDEN CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 292 SWEDEN PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 293 SWEDEN CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 294 SWEDEN KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 295 SWEDEN CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 296 SWEDEN OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 297 SWEDEN CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 298 SWEDEN HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 299 BELGIUM CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 300 BELGIUM FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 301 BELGIUM CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 302 BELGIUM CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 303 BELGIUM CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 304 BELGIUM STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 305 BELGIUM GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 306 BELGIUM NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 307 BELGIUM SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 308 BELGIUM NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 309 BELGIUM SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 310 BELGIUM CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 311 BELGIUM CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 312 BELGIUM PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 313 BELGIUM CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 314 BELGIUM KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 315 BELGIUM CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 316 BELGIUM OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 317 BELGIUM CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 318 BELGIUM HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 319 DENMARK CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 320 DENMARK FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 321 DENMARK CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 322 DENMARK CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 323 DENMARK CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 324 DENMARK STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 325 DENMARK GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 326 DENMARK NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 327 DENMARK SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 328 DENMARK NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 329 DENMARK SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 330 DENMARK CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 331 DENMARK CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 332 DENMARK PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 333 DENMARK CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 334 DENMARK KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 335 DENMARK CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 336 DENMARK OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 337 DENMARK CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 338 DENMARK HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 339 FINLAND CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 340 FINLAND FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 341 FINLAND CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 342 FINLAND CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 343 FINLAND CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 344 FINLAND STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 345 FINLAND GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 346 FINLAND NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 347 FINLAND SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 348 FINLAND NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 349 FINLAND SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 350 FINLAND CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 351 FINLAND CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 352 FINLAND PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 353 FINLAND CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 354 FINLAND KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 355 FINLAND CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 356 FINLAND OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 357 FINLAND CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 358 FINLAND HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 359 NORWAY CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 360 NORWAY FIBRO CARTILAGE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 361 NORWAY CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 362 NORWAY CELL-BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 363 NORWAY CHRONDOCYTE TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 364 NORWAY STEM CELLS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 365 NORWAY GROWTH FACTOR IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 366 NORWAY NON-CELL BASED IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 367 NORWAY SCAFFOLDS IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 368 NORWAY NATURAL IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 369 NORWAY SYNTHETIC IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 370 NORWAY CELL-FREE COMPOSITES IN CARTILAGE REGENERATION MARKET, BY TREATMENT MODALITY, 2022-2031 (USD THOUSAND)
TABLE 371 NORWAY CARTILAGE REGENERATION MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 372 NORWAY PALLIATIVE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 373 NORWAY CARTILAGE REGENERATION MARKET, BY APPLICATION SITE, 2022-2031 (USD THOUSAND)
TABLE 374 NORWAY KNEE IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 375 NORWAY CARTILAGE REGENERATION MARKET, BY SURGICAL PROCEDURE, 2022-2031 (USD THOUSAND)
TABLE 376 NORWAY OSTEOCHONDRIAL TRANSPLANTATION IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 377 NORWAY CARTILAGE REGENERATION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 378 NORWAY HOSPITALS AND CLINICS IN CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 379 REST OF EUROPE CARTILAGE REGENERATION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
図表一覧
FIGURE 1 U.S. & EU CARTILAGE REGENERATION MARKET: SEGMENTATION
FIGURE 2 U.S. & EU CARTILAGE REGENERATION MARKET: DATA TRIANGULATION
FIGURE 3 U.S. & EU CARTILAGE REGENERATION MARKET: DROC ANALYSIS
FIGURE 4 U.S. & EU CARTILAGE REGENERATION MARKET: REGIONAL VS COUNTRYMARKET ANALYSIS
FIGURE 5 U.S. & EU CARTILAGE REGENERATION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. & EU CARTILAGE REGENERATION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.S. & EU CARTILAGE REGENERATION MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 U.S. & EU CARTILAGE REGENERATION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 U.S. & EU CARTILAGE REGENERATION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 U.S. & EU CARTILAGE REGENERATION MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF OSTEOARTHRITIS AND RISING HEALTHCARE EXPENDITURE ARE DRIVING THE GROWTH OF THE U.S. & EU CARTILAGE REGENERATION MARKET FROM 2024 TO 2034
FIGURE 12 HYALINE CARTILAGE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. AND EU CARTILAGE REGENERATION MARKET IN 2024 TO 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE U.S. & EU CARTILAGE REGENERATION MARKET
FIGURE 14 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, 2023
FIGURE 15 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 16 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, CAGR (2024-2031)
FIGURE 17 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY TYPE, LIFELINE CURVE
FIGURE 18 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, 2022
FIGURE 19 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, 2024-2031 (USD THOUSAND)
FIGURE 20 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, CAGR (2024-2031)
FIGURE 21 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT MODALITY, LIFELINE CURVE
FIGURE 22 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, 2022
FIGURE 23 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 24 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, CAGR (2024-2031)
FIGURE 25 U.S. & EUROPE CARTILAGE REGENERATION MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 26 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, 2023
FIGURE 27 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, 2024-2031 (USD THOUSAND)
FIGURE 28 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, CAGR (2024-2031)
FIGURE 29 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY APPLICATION SITE, LIFELINE CURVE
FIGURE 30 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE , 2023
FIGURE 31 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE , 2024-2031 (USD THOUSAND)
FIGURE 32 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE, CAGR (2024-2031)
FIGURE 33 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY SURGICAL PROCEDURE, LIFELINE CURVE
FIGURE 34 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, 2023
FIGURE 35 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 36 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, CAGR (2024-2031)
FIGURE 37 U.S. & EUROPE CARTILAGE REGENERATION MARKET : BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE CARTILAGE REGENERATION MARKET: SNAPSHOT (2023)
FIGURE 39 U.S. CARTILAGE REGENERATION MARKET: COMPANY SHARE 2023 (%)
FIGURE 40 EUROPE CARTILAGE REGENERATION MARKET: COMPANY SHARE 2023 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
